Skip to main content

Table 1 Characteristics of patients

From: Sirt1 expression is associated with CD31 expression in blood cells from patients with chronic obstructive pulmonary disease

Characteristics Smoking control Mild COPD Moderate COPD Severe COPD
GOLD - Stage I Stage II Stage III, IV
Number of patients 106 69 103 80
Age (years) 70.5 ± 9.4 72.2 ± 9.3 72.5 ± 8.8 73.9 ± 8.7
Gender (Male/Female) (102/4) (65/4) (98/5) (76/4)
FVC predict (%) 97.2 ± 14.2 114.1 ± 14.9* 97.3 ± 16.1 75.7 ± 18.1*
FEV1/FVC (%) 77.3 ± 6.1 64.5 ± 5.1* 52.8 ± 9.1* 39.3 ± 10.4*
FEV1% predict 96.1 ± 13.5 96.3 ± 13.3 64.5 ± 8.8* 37.5 ± 8.1*
LAA (%) 5.5 ± 6.1 10.7 ± 10.0 14.6 ± 10.7* 22.7 ± 14.6*
Smoking (Pack years) 61.4 ± 38.5 58.1 ± 33.7 60.5 ± 30.7 63.2 ± 29.2
Current smoker (no.) 31 22 29 19
Medication (no.)
 LABA - 17 49 50
 LAMA - 17 46 55
 ICS - 11 36 38
CRP (mg/dl) 0.24 ± 0.34 0.31 ± 0.48 0.39 ± 0.77 0.46 ± 0.92
  1. COPD Chronic obstructive pulmonary disease, GOLD Global Initiative for Obstructive Lung Disease, FEV1 % predict Forced Expiratory Volume in 1 s % predicted, LAA Low attenuation area; change in FEV1 as a percent of baseline FEV1, LABA Long acting beta 2 agonist, LAMA Long acting muscarinic antagonist, ICS Inhaled corticosteroid
  2. Values are expressed as means ± SD. * p < 0.05 vs smoking control